Health committee  All of us have a very focused field of investigation, so I won't speak in general terms. One commonality in many diseases is inflammation. Arthritis is an inflammatory disease. Some neurological conditions are inflammatory diseases. We're discovering that even infectious diseas

Health committee  That's historical. I can't answer that question.

Health committee  The reason you carry two Aspirin around is not for a risk of acquiring HIV. It's for heart disease. I think Aspirin is a good example. These drugs are very complex and have many different mechanisms. The mechanism Aspirin uses to prevent stroke or a heart attack is different from

Health committee  I think a couple of things could be done. Continued support and growth of basic biomedical discovery research, I think, is important. As was pointed out, you never know where it's going to end up, but it's improving knowledge, and that has resulted in development of antibiotics a

Health committee  We are talking about a baby dose of Aspirin, 81 milligrams. It wouldn't be our recommendation that everyone who is at low risk of acquiring HIV take aspirin. This would be a focused intervention for people who are at extremely high risk—for example, sex workers or others who face

Health committee  That's an excellent point. Most people around the world who are at risk of HIV, for example, are extremely poor. They don't have private insurance coverage. Governments could make the decision to invest in very inexpensive generic drugs that would help prevent some of these disea

Health committee  No, sorry. Could you repeat that?

Health committee  To be honest, I don't know that answer. Again, having more focus in the modelling would be appropriate, but I don't have a number.

Health committee  Yes. Thanks for the question. I think that's very much the case. There are several barriers for moving new ideas to translation into patients. The clinical trial just costs so much money, so I do think there would be significant advantages if there were some mechanism to fund th

Health committee  Thank you very much, Mr. Chair, and thank you to the committee for the opportunity to present. My name is Keith Fowke, and I'm a researcher based at the University of Manitoba. I'm the head of my department of medical microbiology and infectious diseases, and I also function as